Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment-Reference-Cited by-同舟云学术

Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment

Published:2008-12 Issue:6 Volume:8 Page:352-355
ISSN:1557-9190
Container-title:Clinical Lymphoma and Myeloma
language:en
Short-container-title:Clinical Lymphoma and Myeloma

Author:

Bladé Joan,Sonneveld Pieter,San Miguel Jesús F.,Sutherland Heather J.,Hajek Roman,Nagler Arnon,Spencer Andrew,Robak Tadeusz,Cibeira M. Teresa,Zhuang Sen H.,Harousseau Jean-Luc,Orlowski Robert Z.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference14 articles.

1. A phase 2 study of bortezomib in relapsed, refractory myeloma;Richardson;New Engl J Med,2003

2. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution;Bladé;Arch Int Med,1998

3. Renal failure in multiple myeloma: reversibility and impact on the prognosis;Knudsen;Eur J Haematol,2000

4. Tubular NF-kappaB and AP-1 activation in human proteinuric renal disease;Mezzano;Kidney Int,2001

5. How does proteinuria cause progressive renal damage?;Abbate;J Am Soc Nephrol,2006

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07

2. Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option;Bone Marrow Transplantation;2022-04-12

3. An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment;Therapeutic Advances in Hematology;2022-01

4. Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma;Cancers;2021-10-04

5. Proteasome inhibitors for multiple myeloma;Japanese Journal of Clinical Oncology;2018-08-09